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Abstract
The overall cure rate for pediatric malignancies is significantly improved to over 75% 
with an estimated 270,000 survivors of childhood cancer in the United States currently. 
The achievement of high cure rates for most pediatric malignancies has been accompa-
nied by a growing population of childhood cancer survivors who are at an increased 
risk for a myriad of health problems resulting from their cancer or its treatment. Some 
cancer-related complications do not become apparent until several years following can-
cer treatment. As the survivors of childhood cancers age, the effects of therapy may be 
exacerbated by effects of aging on organ function. Late effects encompass a variety of 
detrimental conditions including organ dysfunction, psychosocial complications, and 
subsequent malignancies that may negatively impact quality of life and may predis-
pose them to early mortality. In contrast to the multitude of publications describing  
treatment-related sequelae in childhood cancer survivors, relatively few provide spe-
cific recommendations for health screening and risk-reduction counseling to guide 
healthcare providers in monitoring this vulnerable population. In this chapter, we will 
summarize the evaluation and management of childhood cancer survivors who may 
be encountered across a wide variety of healthcare settings, salient issues influencing 
healthcare for childhood cancer survivors, of which guidelines currently available and 
limitations in current practice.
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1. Introduction
Over 12,400 children and adolescents younger than 20 years of age are diagnosed with can-
cer in the United States every year [1]. Survival for many pediatric cancers has improved 
significantly in the past three decades with improvement in therapies. The surveillance, 
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 epidemiology, and end results data estimate that the overall five-year survival rate among 
children for all cancer sites combined improved from 58% for patients diagnosed in 1975–1977 
to 80% for those diagnosed in 1996–2003 [1].
There were an estimated 388,501 survivors of childhood cancer in the United States as of 
January 1, 2011, of whom 83.5% are ≥5 years after diagnosis [2]. Frequently, long-term sur-
vivors of childhood cancer report late cancer-related effects that diminish quality of life and 
persisting after cancer treatment may result in premature onset of common diseases associ-
ated with aging such as obesity, diabetes mellitus, cardiovascular disease, hypertension, and 
second cancers [3–5].
Risk-based health care that involves a personalized plan for surveillance, screening, and pre-
vention is recommended to reduce cancer-related morbidity in childhood cancer survivors. 
However, there are few consensus recommendations and very few specialized centers pro-
viding this care. Moreover, to implement this model, the survivor and healthcare provider 
must have accurate information about cancer diagnosis, treatment modalities, and potential 
cancer-related health risks to guide screening and risk-reducing interventions. Childhood 
Cancer Survivor Study (CCSS) data show that approximately half of the approximately 14,000 
responding long-term survivors of childhood cancer had not been seen by a physician during 
the previous 2 years for evaluation of cancer-related problems. A recent survey of Pediatric 
Oncology Group and Children’s Cancer Group member sites reported that 44% of the sites 
have a mechanism for following adult survivors, but only 15% of the programs have a formal 
database for these patients [6].
In this chapter, we describe the common late effects based on therapy received for cancer 
and provide the current evidence regarding guidelines available for long-term follow-up of 
pediatric cancer survivors. We also address the lacunas in patient and physician education 
and current evidence regarding interventions to address this to improve the quality of life for 
pediatric cancer survivors.
2. Late effects of cancer therapy
Late effects are those toxicities related to therapy for cancer that are absent or subclinical 
at the end of therapy but manifest later. Compensatory mechanisms that initially maintain 
the function of injured organs may fail with growth, development, and aging. We discuss 
below the common late effects of cancer chemotherapy in children. Table 1 summarizes the 
most common late effects in survivors of childhood cancer. Tables 2 and 3 summarize some 
of the common late effects and screening methodology used to monitor and manage them.
2.1. Mortality
Type and intensity of therapy as well as the patient’s age at therapy determine not only the 
overall survival but also the frequency of late effects of cancer therapy [7]. Some studies 
have shown excessive mortality rates in five-year survivors of childhood cancer [8–12]. The 
Childhood Cancer Survivor Study (CCSS), a retrospective cohort study initiated in 1994, was 
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Adverse event category
Alopecia
Ear, nose, and throat
Fatigue
Pain
Pulmonary
Tissue hypoplasia
Urology
Miscellaneous
Ophthalmology
Gastroenterology
Cardiovascular
Angina pectoris/Myocardial infarction
Cardiomyopathy
Nephrologic
Hypertension
Tubular dysfunction
Orthopedic
Amputation/Prothesis/Rotationplasty
Scoliosis/Low back pain
Psychosocial/Cognitive problems
Cognitive problems
Emotional problems
Fertility
Oligospermia/Azoospermia
Metabolic
Obesity
Second tumors
Malignant
Endocrine
Growth hormone deficiency
Thyroid disorders
Panhypopituitarism
Neurologic
Seizures
Motor dysfunction/Hemiparesis
Sensory loss
Table 1. Common adverse events in a cohort of childhood cancer survivors.
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designed to study late effects among long-term survivors of childhood cancer. It showed a 
10.8-fold excess in overall mortality. Risk of death was significantly higher in females, those 
with an initial diagnosis of leukemia or brain tumor and those diagnosed with cancer before 
they turned 5 years old. Sixty percent of deaths were from recurrence of the original cancer 
that was the leading cause of death. Statistically significant excess mortality rates were seen 
due to various causes shown in Table 4. Treatment-related associations were reported for 
cancer mortality (radiation, epipodophyllotoxins, alkylating agents), cardiac mortality (chest 
irradiation), and other deaths (radiation, anthracyclines). No excess mortality was seen for 
external causes [13].
Organ Therapy Screening test
Musculoskeletal Radiotherapy(RT) Physical exam scoliosis exam (annually if growing), X-ray pm
Breast Mediastinal RT Breast exam. mammography beginning age 25–30
CNS Cranial RT Neurocognitive testing (baseline, q 3-5 yrs pm). MRI (baseline)
Neuroendocrine Hypothala/mic-pituitary RT Growm curve q yr. bone age (age 9)
GH stimulation test
TSH, Free T4.T3 (baseline q 3-5 yr pm)
LH FSH. test/est. prolactin (baseline, pm)
8 am cortisol (baseline, pm)
Cardiac Anthracyclines  
mediastinal T-spine RT 
ECHO’EKG (baseline for all; q 3-5 yr after anthracycline) 
Holter q 5 yrs pm (high-dose anthracycline) Stress test/
dobutamine stress echo pm (after RT)
Pulmonary RT PFT baseline, q 3-5 yrs pm
Bleomycin, CCNU/BCNU
Ovary Alkylating agents Menstrual Ήx annually
RT LH FSH estradiol baseline (age>12) and pm
Testes Alkylating agents LH FSH. testos baseline (age >12) and pm
RT Spermatoanalysis pm
Renal Cisplatin (carboplatin), Creatinine, Mg, q 1-2 yrs
Ifosfamide, Ceatinine clearance baseline and q 3-5 yrs pm
RT Urinalysis (RT. ifosfamide)
Ifosfamide: serum phosphate. urine glucose, protein
Bladder Cyclophosphamide, Urinalysis annually for heme
Ifosfamide. RT
Thyroid RT to neck, mediastinum TSH, FreeT4,T3q yr X 10
Scans (U/S) pm
Liner 6-MP7MTX,Act-d, RT Liver function tests every 1–3 years
GI Intestinal RT Stool guiac q yr, colonoscopy (ACS)
Table 2. Example of screening methodology for late effects specific to treatment received.
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Chemotherapy 
If patient received: 
 Actinomycin or antimetabolite ALT Periodically
Bone densitometry Optional
 Aminogtycoside, high dose Audiology Optional
 Anthracycline Echocardiogram Every 3 years
(≥300 mg/m2, or anthracycline administered prior 
to age 1 year 
EKG Optional
or ≥200 mg/m2 with radiation involving the chest)
 BCNU, CCNll, bleoraycin CXR Baseline
Pulmonary function tests Baseline and as needed
 Cisplatin BUN, creatinine, magnesium Annually
Audiology Optional
 Corticosteroids Bone deisitometry Optional
 Cyclophosphamide FSH, LH, estradiol Optional
Semen analysis Optional
Urinalysis Annually
Urine cytology Optional
 Cyclosporine Bone densitometry Optional
 Etoposide CBC with platelets and differential Annually
 Nitrogen mustard, procarbazine CBC with platelets and differential Annually
FSH, LH, estradiol Optional
Testosterone Optional
Semen analysis Optional
 Vinciistine ALT Periodically
Radiation therapy
If patient received;
 Cranial or craniospinal radiation Cataract screening Periodically
Audiology Optional
Dental screening Annually
TSH, Free T4 Annually
Lipid profile Annually
Bone densitometry Optional
 Mande radiation TSH Annually
Lipid profile Annually
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Mammogram (females) Start 8 years after 
radiation, then 
annually
Plain radiographs of irradiated site Optional
 Abdominal radiation Hernoccult screening Annually
Urinalysis Annually
 Pehic radiation FSH.LH Optional
Semen analysis Optional
 High-dose radiation of the Hunk or extremities Plain radiographs of the irradiated 
sites 
Optional
Surgery
If patient received:
 Nephrectomy BUN, creatinine, urinalysis Annually
 Splenectomy Verify immunizations Annually
Antibiotic prophvlaxis Optional
Table 3. Organ-specific late effects of cancer therapy and screening methodology.
-Recurrence
-Treatment-related consequences
Subsequent neoplasm
Lip, oral cavity, pharynx, lung
Digestive organs and peritoneum
Bone and articular cartilage
Connective and other soft tissue
Melanoma and other skin
Breast
Genitourinary organs
Brain and other parts of nervous system
Lymphatic and hematopoietic
Other subsequent cancer
Cardiac
Ischemic heart disease
Cardiomyopathy
Congestive heart failure
Other cardiac
Pulmonary
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2.2. Growth and development
The effects on growth and development are dependent on dose and the developmental pro-
cess of the organ in question. Therapy for the treatment of malignancy may interfere with 
development in terms of physical growth, neurocognitive growth, musculoskeletal growth 
(hypoplasia), and, ultimately, pubertal development.
2.3. Physical growth
Growth is often impaired in children with active cancer and those undergoing intense thera-
pies due to hypermetabolic states, the effects of chronic disease, and poor nutrition. After 
the completion of therapy, many children experience a growth spurt and normalization of 
growth but specific therapies may interfere with this [14].
2.3.1. Hypoplasia
Localized radiotherapy affects skin and musculoskeletal growth causing cosmetic concern in 
radiation-treated survivors. Asymmetric radiation fields result in differential growth of the 
radiated versus nonirradiated tissue. Functional effects, such as muscle or back pain due to 
Pulmonary fibrosis
Other pulmonary
Other sequelae
Infectious disease
Other sequelae
-Nontreatment-related causes of death
External causes
Motor vehicle accident
Other accident
Suicide
Homicide
Medical conditions
Human immunodeficiency virus
Pneumonia
Other bacterial/viral infection
Heart disease
Cerebrovascular disease
Other medical condition
Table 4. Specific causes of mortality in Childhood Cancer Survivor Study cohort.
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radiation-induced scoliosis, can occur. Hypoplasia is not apparent at the end of therapy but 
becomes manifest with growth, particularly during the pubertal spurt. Particular sensitivity 
of adipose tissue to radiation may lead to asymmetric fat distribution with weight gain any 
time in life. Breast asymmetry occurs after unilateral chest radiotherapy prior to maturity. 
Doses of 20 Gy may stop breast development completely, whereas 10 Gy to the breast bud 
may cause hypoplasia [15, 16]. Lactation may not be possible for women [17].
2.3.2. Linear growth effects
Cranial irradiation affects linear growth by its effect on the hypothalamic-pituitary axis. 
The effect is dependent on dose and age. Patients treated with large doses of whole brain 
radiotherapy are likely to have growth hormone deficiency requiring hormone replacement. 
Growth velocity after lower doses of radiotherapy may proceed normally until puberty, at 
which time the classic “growth spurt” may be impaired [18]. Early onset of puberty is com-
mon after cranial radiation, reducing final height [18] and this effect is more pronounced if 
the child is younger at the time of radiation [19]. Childhood cancer survivors treated with 
cranial radiation may have a higher body mass index [20], which is inversely related to the age 
of puberty [21, 22]. After spinal radiotherapy, the effect of aberrant growth hormone release 
and early puberty may be worsened by vertebral stature loss after spinal irradiation [23]. 
These effects can be mitigated prior to closure of the epiphyses. Close monitoring of growth is 
needed but may not be sufficient. The role of growth hormone stimulation beginning shortly 
after completion of therapy and inhibition of the pubertal spurt to prolong the potential 
growth phase is being assessed [19].
2.3.3. Intellectual development
Intellectual outcome after the completion of therapy is important for integration success-
fully into society after completion of therapy. Central nervous system (CNS) radiotherapy or 
high-dose chemotherapy that achieves sufficient CNS levels for the prevention of meningeal 
leukemia may result in cognitive deficits [24]. Impairment of memory, attention, and visual 
perceptual motor skills result in problems with language, reading, and arithmetic and poor 
academic achievement [24, 25]. Brain injury may become more apparent years after the com-
pletion of therapy and intellectual growth suffers over time [26]. The severity of the effect is 
determined by both dose of therapy and the time at which it was given. Higher doses [>36 Gy] 
have significant deficits that virtually always require special educational efforts [27]. Cognitive 
effects of radiation on infant development are profound and hence high doses may be deferred 
until after age two [27]. Preschool children receiving doses in the range of 18–24 Gy of cranial 
radiotherapy often require special educational resources, and older children may have diffi-
culties with complex systems such as a new language or high-level mathematics [27]. At lower 
doses of radiation, children are likely to remain within the mainstream education efforts but 
may need help to achieve maximal success. Significant doses of intrathecal chemotherapy may 
have similar effects [27]. Most survivors enter college at the same rates as siblings, except for 
those receiving 24 Gy or treated as preschoolers; however, an overall need for special educa-
tion exists and occupational success may not be equal to that of siblings [28].
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2.4. Organ specific effects
2.4.1. Gonadal toxicity and pubertal development
It is tough to clinically assess the extent of treatment-induced gonadal damage suffered dur-
ing childhood. Anticipatory guidance can be given based upon reported experience. Close 
monitoring throughout puberty is vital as initial pubertal development may proceed even 
with severe gonadal injury as a result of adrenal corticoid hormones. Long delays in assess-
ment may have severe social consequences.
Alkylating agents are known for inducing infertility; little gonadal toxicity is noted after the 
antimetabolites, vinca alkaloids, anthracyclines, bleomycin, or platinum derivatives. Sertoli 
cells are more sensitive than Leydig cells to radiation and alkylating agents [29, 30]. Young 
boys may proceed with normal masculinization, potency, and libido even with azoospermia 
due to preservation of Leydig cells. Testosterone levels as well as pubertal development should 
be assessed for recipients of high-dose chemotherapy. By late puberty, testosterone deficiency 
should be treated to normalize masculinization. Even though ovaries are less sensitive than 
testes to gonadotoxic agents [30, 31], an affected female child may experience pubertal delay 
and amenorrhea. Hormone replacement to preserve feminization and periods may be needed. 
Another reason for treating estradiol deficiency is the prevention of osteoporosis and early 
coronary artery disease. Cranial radiation at higher doses can also result in secondary gonadal 
insufficiency by impairment in LH/FSH production and secretion. In those brain tumor 
patients receiving hypothalamic-pituitary axis radiation as well as alkylating agents (e.g., 
BCNU, CCNU), direct gonadal effects as well as secondary gonadal insufficiency are seen [31].
Reversibility is dependent on dose of gonadal radiation or alkylating agents. Ovarian func-
tion is unlikely to recover long after the immediate therapy due to loss of ova. The testis is 
more sensitive to cytotoxic therapies than the ovary, but late recovery (2–12 years after radio-
therapy) has been reported [32]. Prediction of fertility in an adult woman may be indicated 
by evaluation of her menstrual cycle. The same dose of drug is more likely to affect an older 
woman than a younger one [33]. Although young women may not become amenorrheic after 
cytotoxic therapy, the risk of early menopause exists. Direct radiotherapy to the ovaries also 
causes infertility. Oophoropexy is commonly offered to prevent infertility in women whose 
ovaries would otherwise remain in the radiation field. Lower doses or even scatter of radia-
tion within the small body of an infant or toddler may have profound effects. Oophoropexy is 
not an option in this population since the small torso does not offer a sanctuary for the ovaries. 
Flank radiotherapy such as for Wilms’ tumor does not affect the ovaries but may result in 
reduced fetal size by effects on the uterine muscle and vasculature [34, 35].
Male sterility is usual after approximately 10 g/m2 of cyclophosphamide. The prepubertal 
state offers, at best, only limited protection to testes treated with cyclophosphamide [36]. Ten 
percent of men will become sterile after one to two cycles of MOPP chemotherapy commonly 
used in Hodgkin’s disease in the past, while 80–100% are sterile after six courses [36]. Low 
doses (2–3 Gy) of radiotherapy result in azoospermia in all males, with late recovery noted 
occasionally after a period of years.
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New reproductive technologies have improved outcomes for infertile cancer survivors. Sperm 
banking, the ability to inseminate ova with only small numbers of spermatozoa, and artificial 
insemination are the most frequently used approaches for sterile male survivors. Female sur-
vivors have more limited options. Storage of ova is being researched actively [37].
Hyperprolactinemia is another easily treatable and fairly common but often missed effect of 
hypothalamic-pituitary irradiation that may impair fertility as well as growth and libido [38]. 
Appropriate endocrinologic interventions with dopamine agonists can be helpful.
2.4.2. Cardiac
Anthracyclines are important in the treatment of most childhood cancers. Unfortunately, car-
diac damage is most pronounced after treatment with anthracyclines, with additive effects of 
cyclophosphamide and radiation therapy. Anthracyclines cause decrease in myocyte number 
by causing myocardial cell death. Residual myocytes hypertrophy in a compensatory manner 
[39]. Cardiac injury during or shortly after the completion of chemotherapy may progress, 
stabilize, or improve after the first year [40]. Patients with reduced cardiac function within 6 
months of completing chemotherapy are at increased risk for the development of late cardiac 
failure [41].
Myocardial injury can be detected with sensitive screening tests, even after a cumulative dose 
of 45 mg/m2 [42, 43]. Unfortunately, these tests are not routinely available. Initial improve-
ment in cardiac function from compensatory changes may diminish with later stressors in 
life. For example, myocardial depressants such as alcohol or increased afterload brought on 
by exercise, growth spurts, or pregnancy may induce late cardiac failure. Isometric exercise 
may increase the risk for late cardiac failure, particularly in after neck or mantle radiotherapy 
[44]. There is evidence to suggest that there is a continuum of injury that will manifest itself 
throughout the lives of these patients [45]. Many pediatric cardiologists may advise patients 
to avoid excessive alcohol intake and isometric exercises such as weight-lifting. Those who 
have received the higher doses of anthracyclines need the closest monitoring and counseling.
Pregnancy, a time of increased cardiac demand, is a dangerous period for anthracycline-
treated women. These women need to be evaluated by a cardiologist. Obstetricians should be 
made aware that these women may have limited ability to compensate for the increased car-
diac output of pregnancy. Careful monitoring during pregnancy and the postpartum period 
is essential. Women with significantly limited cardiac reserve may be advised that pregnancy 
may carry unacceptable risk [44].
Severe cardiac effects of radiation may be noted including valvular damage, pericardial thick-
ening, and ischemic heart disease [46]. Patients have an increased risk of both angina and 
myocardial infarction years after radiotherapy for Hodgkin’s disease [47], with a relative risk 
of 3.1 for cardiac death with Hodgkin’s disease [48]. This risk was noted in those receiving 
>30 Gy of mantle irradiation and was greatest for those treated before 20 years of age [49]. The 
use of anteriorly weighted ports, reduction in total tumor and daily fraction dose, and cardiac 
shielding are some of the techniques being used to reduce the effects of radiation [49].
Pediatric Cancer Survivors88
2.4.3. Pulmonary
The effects of chemotherapy on the lungs may be lethal or may improve gradually. However, 
pulmonary function tests may not return to normal, and there may be slow clinical decline. 
Long-term outcome depends on severity of the acute injury, the extent of compensation, and 
the likelihood of decompensation. It is reported that 35% of children treated for brain tumors 
with nitrosourea and radiotherapy died of pulmonary fibrosis, 12% within 3 years and 24% 
after a symptom-free period of 7–12 years [50]. Therefore, the recommended dose limit of 
nitrosourea’s in children has been lowered from 1500 to 750 mg/m2 but the late effects of 
this lower dose need to be assessed [50]. Some chemotherapy drugs like cyclophosphamide 
when used orally may cause restrictive lung disease by inhibition of chest wall growth. This 
effect may become apparent as late as 7 years after the completion of therapy [51]. It has not 
been reported after modern intravenous cyclophosphamide regimens. Patients treated with 
bleomycin may experience pulmonary insufficiency from interstitial pneumonitis character-
ized by a reticulo-nodular pattern [52, 53]. Even after the completion of therapy, the risk for 
overt decompensation remains for at least 1 year. A recent study by Kung et al. has noted 
that 22% of Hodgkin’s disease patients with normal pulmonary function tests at the end of 
therapy developed abnormalities with follow-up of 1–7 years [54, 55]. In long-term follow-up, 
pulmonary dysfunction is usually subclinical. Subconscious avoidance of exercise is rarely 
attributed to therapy or recognized by the patient himself. Patients who have been treated 
with pulmonary radiation and cytotoxic agents such as BCNU, CCNU, and bleomycin should 
undergo pulmonary function testing every 5–8 years [56]. Such patients should avoid expo-
sure to pulmonary toxins, most notably cigarettes. Radiation itself (>9 Gy) raised the risk of 
lung cancer after Hodgkin’s disease.
2.4.4. Genitourinary tract
The most commonly noted renal problems after radiation therapy, especially with doses 
greater than 20 Gy are tubular damage and hypertension associated with renal artery steno-
sis [57, 58]. Children may be susceptible to these complications at lower doses. In addition, 
chemotherapy may exacerbate these effects [59]. Chemotherapy alone, particularly platinum 
compounds are notorious for glomerular and tubular injury [60, 61]. Glomerular injury may 
recover over time, while tubular injury persists. The nitrosourea may affect glomerular func-
tion. Ifosfamide results in renal Fanconi’s syndrome with glycosuria, phosphaturia, and ami-
noaciduria [62]. Hypophosphatemia may result in slow growth and bone disease. Glomerular 
filtration may also be affected by ifosfamide. In children, there is a risk of renal decompensa-
tion with growth with any of these injuries. The bladder is susceptible to cytotoxic agents such 
as cyclophosphamide and ifosfamide that have acrolein as a by-product. Acrolein may result 
hemorrhage cystitis, fibrosis, diminished bladder volume, and rarely bladder cancer [63–65]. 
Patients who have received one of these agents should have an annual urinalysis, with further 
evaluation if hematuria is noted. Radiation may induce bladder fibrosis, decreasing contract-
ibility and decreased volume depending on dose and area exposed [66]. Scarring may also 
diminish function of the urethra and ureter.
Long-Term Survivors of Childhood Cancer: The Late Effects of Therapy
http://dx.doi.org/10.5772/67366
89
2.4.5. Thyroid gland
Damage to thyroid is common after radiotherapy to the neck and chest. Patients treated for 
Hodgkin’s disease in whom the thyroid was irradiated had a 47% risk of overt or compensated 
hypothyroidism at 26 years [67]. Although compensatory increase in thyroid-stimulating hor-
mone (TSH) initially maintains the euthyroid clinical state, further deterioration of thyroid 
function often results in clinical symptomatology. Treatment with thyroid hormone is recom-
mended with persistent evidence of compensated hypothyroidism. Chronically elevated TSH 
levels in the presence of irradiated thyroid tissue can enhance tumor development [68, 69]. 
Benign nodules, Graves’ disease, thyroid cancer, and Hashimoto’s thyroiditis are some of the 
other disorders seen after radiation to the gland [67].
2.4.6. Gastrointestinal/hepatic
There is not much literature describing long-term effects to this system. This may be due to 
long latency of the late effects or under detection. Many chemotherapeutic agents as well as 
radiotherapy may be damaging to the liver; therefore, it may be difficult to attribute the harm 
to specific therapy. Transfusions increase the risk of viral hepatitis. Hepatitis C has been iden-
tified in increasing numbers of survivors [70]. Fibrosis and adhesions of bowel are known to 
occur after radiotherapy.
2.4.7. Second malignancies
About 4% of survivors develop a secondary malignancy within 25 years of diagnosis of the 
primary cancer [71]. This is an excess risk of six times among survivors compared to healthy 
individuals and is contributed to by the carcinogenic effects of treatments for the original 
childhood cancer as well as to genetic predisposition [71]. Bone cancers, mostly osteosarco-
mas, are the most common solid second cancers observed after all types of childhood cancer 
other than retinoblastoma [72, 73]. There is probably some element of genetic predisposition, 
which would include, for example, constitutional mutations of the p53 gene that contributes 
to secondary cancers after childhood cancers [74, 75]. Second primary leukemia is diagnosed 
in about 0.2% of survivors of childhood cancer within 6 years of diagnosis of the original 
cancer—about eight times the expected number of leukemia [76].
2.4.8. Education, psychosocial, and quality of life issues
Evidence suggests that survivors of childhood cancer experienced a range of educational, 
behavioral, and social problems. The extent of problems experienced varies by the disease 
and its treatment, as well as by demographic and family variables [77, 78]. Children miss sub-
stantial amounts of schooling during treatment, and this affects both academic achievement 
and social relationships. Fairly consistent evidence shows that intrathecal chemotherapy and 
radiotherapy to the CNS impacts academic achievement and learning. Children under 5 years 
at diagnosis are particularly vulnerable. A general decline in intellectual function or deficits 
in specific skills, including attention, concentration, and mathematical reasoning may be seen 
[79, 80]. Measurement of social function is more complex than measurement of academic 
Pediatric Cancer Survivors90
function, and perhaps for this reason there is limited literature describing social functioning 
among survivors. Among children of school age, there is some evidence that survivors of a 
central nervous system tumor are less popular with other children [81]. Many survivors need 
appropriate and sensitive counseling to enable them to choose and succeed in appropriate 
employment [82]. There is a considerable variation in quality of life among survivors [82]. 
Several studies report compromises in mental health among survivors [82].
3. Prevention of late effects
Several agents designed to protect normal tissues from the toxic effects of specific therapeutic 
agents are being evaluated. Examples of these agents include amifostine (cisplatinum-induced 
ototoxicity) [83] and dexrazoxane (anthracycline-induced cardiomyopathy) [84]. Long-term 
follow-up will be required to assess the efficacy of all these strategies. Research related to 
determination of whether agents used to protect normal tissues will or slow down the progres-
sion of an adverse late effect, is less well developed. Specific research initiatives include the use 
of afterload reducing agents for prevention of further progression of myocardial dysfunction 
[85], use of chemoprevention for prevention of secondary malignancies, lifestyle and behavior 
modification, and education to increase awareness of the need for screening for early detection.
3.1. Guidelines for follow-up of pediatric cancer survivors
Awareness of the potential health problems as a result of treatment for cancer in childhood is 
less than optimal among practitioners and survivors themselves. In contrast to the multitude 
of publications describing treatment-related sequelae in childhood cancer survivors, relatively 
few provide specific recommendations for health screening and risk-reduction counseling to 
guide healthcare providers in monitoring this vulnerable population [5, 86–90]. To reach this 
goal, several barriers need to be surpassed, notably education of survivors and healthcare 
providers regarding the late effects of cancer treatment; availability of standardized guide-
lines for follow-up of the survivors in a feasible and practical setting and ongoing commu-
nication between the cancer center that provided acute care for the patient and the facility 
providing follow-up care. Among the hurdles to guideline development are ongoing changes 
in pediatric cancer therapy, long latency periods required to evaluate many late effects, the 
unknown effects of aging, and the multiple factors known to influence cancer-related health 
risks in patients who received cancer therapy during childhood [86, 91]. Despite these chal-
lenges, two sets of clinical follow-up guidelines designed to guide care for pediatric cancer 
survivors have recently been published and are described below.
3.1.1. Children’s Oncology Group (COG) Long-Term Follow-up (LTFU) Guidelines
The COG is a 242-member National Cancer Institute-supported cooperative clinical trials 
group whose goals include minimizing the risk of long-term effects that may impact dura-
tion and/or quality of life in pediatric cancer survivors. COG recently developed risk-based, 
exposure-related guidelines (Long-Term Follow-up Guidelines for Survivors of Childhood, 
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Adolescent, and Young Adult Cancers] for use in directing follow-up care for survivors of 
pediatric malignancies [86].
The COG-LTFU Guidelines are risk-based, exposure-related clinical practice guidelines for 
screening and management of late effects resulting from therapeutic exposures used during 
the treatment of pediatric malignancies. The guidelines are both evidence-based and based 
on the collective clinical experience of experts (matching the magnitude of the risk with the 
intensity of the screening recommendations). The screening recommendations are provided 
in these guidelines area consensus statement from a panel of experts in the late effects of 
pediatric cancer treatment. A therapy-based design was chosen to permit formatting of the 
guidelines by therapeutic exposure since the therapeutic interventions for a specific pediat-
ric malignancy may differ considerably based on the patient’s age, presenting features, and 
treatment era [86]. The guidelines are therefore organized according to therapeutic agent, 
and cross-referenced to other topics with related toxicities. The guidelines are designed to 
standardize and direct follow-up care that facilitates early identification of and interven-
tion for treatment-related complications. Limitations include the potential for false-positive 
screening evaluations and increased patient anxiety related to an increased awareness of 
possible complications. Costs of long-term follow-up care may also be prohibitive for some 
patients.
Goal of implementation of these guidelines is to increase quality of life and decrease com-
plication-related healthcare costs for pediatric cancer survivors by providing standardized 
and enhanced follow-up care throughout the life span. The guidelines are intended for 
use beginning 2 or more years following the completion of cancer therapy to [1] promote 
healthy lifestyles [2], provide ongoing monitoring of health status [3], facilitate early iden-
tification of late effects, and [4] provide timely intervention for late effects. The informa-
tion within these guidelines is important for clinicians (e.g., physicians, nurse practitioners, 
physician assistants, nurses) in the fields of pediatrics, oncology, internal medicine, family 
practice, and gynecology, as well as subspecialists in many fields (e.g., endocrinology, car-
diology, pulmonology) [86]. Figure 1 presents an example model of how these guidelines 
were developed.
3.1.2. SIGN guidelines
The goal of Scottish Intercollegiate Guidelines Network (SIGN) is to develop evidence-
based clinical guidelines aimed at reducing variations in clinical practice and outcomes 
for patients [91]. SIGN is composed of members from all medical specialties, nursing, 
pharmacy, dentistry, allied health professionals, patients, health service managers, social 
services, and researchers [91]. SIGN recently developed national guidelines for pediatric 
cancer survivors (SIGN guidelines ) [91].The SIGN guideline provides a detailed review 
of the following topics with evidence for each and grading for each recommendation and 
its rationale: (1) assessment and achievement of normal growth; (2) achievement of nor-
mal progression through puberty and factors affecting fertility; (3) early identification, 
assessment and treatment of cardiac abnormalities; (4) assessment of thyroid function; 
and 5] assessment and achievement of optimum neurodevelopment and psychological 
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health [92, 93]. Limitations of the SIGN guideline include lack of specific follow-up rec-
ommendations for areas such as renal, pulmonary, gastrointestinal, ocular, auditory, and 
musculoskeletal systems as well as second malignancies. In addition to clinical recommen-
dations, the SIGN guideline contains  recommendations for the delivery of follow-up care 
for pediatric cancer survivors, based on the intensity of treatment received. The degree of 
long-term risk is determined by site of the underlying malignancy, type and intensity of 
treatment, and age of patient at treatment. Three levels of follow-up are described: “Level 
1” follow-up is suggested for those survivors for whom the benefit of clinical follow-up 
is not clearly established. Annual or even every two-year postal or telephone contact is 
recommended. “Level 2” follow-up is suggested for the majority of patients on current 
protocols. Nurse or primary care follow-up on an annual basis may suffice. “Level 3” 
follow-up is for patients who have received radiotherapy, bone marrow transplanta-
tion, or megatherapy, and who have a significant risk of long-term morbidity [92, 93]. 
Recommendations for these patients include follow-up in a medically supervised long-
term follow-up clinic three to four times per year [92, 93].
3.1.3. Application of guidelines to clinical practice
The main challenge of providing quality care to a pediatric cancer survivor is combining 
routine age-appropriate health maintenance with exposure-related screening for potential 
late-onset complications related to pediatric cancer therapy. Ideally, evaluations should be 
individualized based on the survivor’s treatment history. A balance between over-screening, 
which might induce anxiety related to unlikely complications, and under-screening for poten-
tially life-threatening complications that if missed at an early phase may require more aggres-
sive intervention later needs to be achieved. Screening guidelines that can be individualized 
based on the patient’s risk for developing a particular complication are therefore ideal. As 
Figure 1. Sample excerpt from the Children’s Oncology Group Long-Term Follow-Up Guidelines for survivors of 
childhood, adolescent, and young adult cancers. TSH, thyroid-stimulating hormone.
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the COG and SIGN guidelines become more widely implemented over time, refinements will 
undoubtedly be made that will make them even more clinically relevant and practical for 
survivors who are followed in future years.
The importance of educating both survivor and healthcare professionals about potential late 
effects cannot be over-emphasized since a wide range of providers are involved in the follow-
up of these patients including nurses, psychologists, social workers, adult and pediatric pri-
mary care providers, and specialists in many fields. Ultimately, as with all clinical practice 
guidelines, decisions regarding implementation of specific screening modalities and ongoing 
clinical management should be tailored to individual patients, taking into consideration all 
relevant factors, including medical and psychosocial history, therapeutic exposures, risk fac-
tors, and co-morbidities [93].
3.1.4. Limitations in providing long-term follow-up care
3.1.4.1. Patient factors
Misperceptions about their cancer diagnosis, treatment, and cancer-related health risks exist 
among cancer survivors [94–96]. Byrne et al. [90] surveyed 1928 adult survivors of child-
hood cancer diagnosed between 1945 and 1974 to assess knowledge of their cancer diagnosis. 
Overall, 14% of survivors were not aware that they had cancer. Lesser knowledge of their 
diagnosis was associated with younger age at treatment, nonwhite race, less intensive treat-
ment, and lower parental education status. It is possible that racial, socioeconomic, and cul-
tural factors that were prevalent during the period when the patient was diagnosed may 
influence the interaction amongst the oncologist and patient [90]. Historically, some health-
care professionals and families prefer giving limited information about cancer-related health 
risk to survivors due to concerns about inducing anxiety. In a similar study from 1970 to 
1986, Childhood Cancer Survivor Study (CCSS) investigators evaluated the accuracy of self-
reported information acquired from a cross-sectional survey of 635 adult survivors of child-
hood cancer. Knowledge about cancer history and its associated health risks is improved in 
more recently treated survivors compared to the Byrne study [94]. More than 90% of partici-
pants were aware of their cancer diagnosis but not all elements of their history in a recent 
study. The knowledge deficits about cancer-related health risks in older survivors may limit 
their participation in screening and risk-reducing programs [97].
3.1.4.2. Provider factors
Healthcare providers encountering childhood cancer survivors must be knowledgeable 
about potential cancer-related adverse effects in order to prescribe appropriate monitor-
ing and interventions should health problems arise. Because of the rarity and complexity of 
numerous histologic subtypes with unique epidemiology, biology, and treatment regimens 
managing long-term childhood cancer survivors is an intimidating task for primary care 
physicians. Healthcare providers are unlikely to care for more than a handful of survivors, 
 usually each with different cancers, treatment exposures, and health risks making it difficult 
to attain proficiency. Consequently, primary healthcare providers in the community are often 
 uncomfortable with supervising the care of childhood cancer survivors.
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The knowledge, attitudes, and beliefs of physicians providing care for survivors of child-
hood cancer have not been well studied. Several investigators coordinating late effects sur-
veyed a convenience sample of 236 physicians from around the United States, in private or 
academic practices using a 36-item questionnaire that asked about knowledge, attitudes, 
and beliefs in providing health care for adult survivors of childhood cancer [98]. In com-
parison with pediatric oncologists, primary care physicians (general internists and family 
physicians) reported a lower level of knowledge regarding both common childhood cancers 
and the late effects with treatment exposures. A recent study in the UK reported a cross-
sectional postal survey as well as a cross-sectional postal survey of general practitioners of 
10,979 adult survivors of childhood cancer in Britain. This study has shown that there are 
wide variations in the extent to which survivors of childhood cancer are discharged from 
hospital follow-up [99]. Adult oncologists generally reported a higher level of knowledge of 
these factors than primary care physicians, but considerably less than pediatric oncologists. 
Notably, primary care physicians expressed a lower level of comfort in managing survi-
vors. These data point to a need for resources and interventions that specifically address 
the unique needs and medical management of childhood cancer survivors that primary care 
providers might benefit from.
3.1.5. Solutions for coordinated care for childhood cancer survivors
3.1.5.1. Specialized long-term follow-up clinics
Multidisciplinary long-term follow-up teams at some pediatric oncology treatment centers 
have established long-term follow-up clinics. Follow-up in this model is limited to an annual 
comprehensive multidisciplinary health evaluation, and survivors are encouraged to estab-
lish an ongoing relationship with a primary healthcare provider in the community for routine 
health maintenance. Benefits of this approach are that the patient remains in contact with a 
team that is knowledgeable and has a standardized program of long-term follow-up care, 
contact with the original treatment center is maintained, and multidisciplinary referrals avail-
able within the healthcare system. Disadvantages include the lack of familiarity of the pediat-
ric treatment team with age related health-care issues that might arise, reluctance of the older 
patient to return to a pediatric facility, reimbursement for specialized services not covered 
by insurance companies, and problems of access due to long distances between the medical 
center and the survivor’s residence [100].
3.1.5.2. Transition models
In some instances, institutions have established formalized transition programs with special-
ized long-term follow-up programs for adult survivors of childhood cancer because of reluc-
tance of pediatric oncology centers to take care of adult cancer survivors. Transition programs 
may utilize both oncology and primary care providers in a collaborative framework, and 
maintain many of the benefits of the specialized long-term follow-up clinics, with the benefit 
of care providers with expertise in adult medicine. One limitation is that since the focus is on 
survivorship care, and ongoing primary care is often not accessible through these specialized 
programs, and distance to the center may remain a barrier [100].
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3.1.5.3. Transition to adult oncology
In this model, when the survivor reaches adulthood, the pediatric provider makes a referral 
to an adult oncologist for ongoing follow-up. Advantages of this system include ongoing 
monitoring for disease recurrence in an adult medical care system, and accessibility to care in 
the local community. Disadvantages include the limited familiarity of most adult oncologists 
with the potential late complications of chemotherapy and radiotherapy in children and the 
appropriate follow-up evaluations indicated for childhood cancer survivors [100].
3.1.5.4. Community-based care
Follow-up care may be provided by an adult primary care provider (e.g., internist, family 
practitioner), who maintains communication with the original pediatric oncology treatment 
team. Advantages of this model include ability to maintain a relationship with a provider in 
the community who is familiar with their specialized healthcare needs and disadvantages 
include the primary care provider’s lack of familiarity with potential late effects. There may 
also be limited access to multidisciplinary specialty care providers that many survivors 
require [100].
4. Conclusions
As pediatric oncologists, our work is not done when the cancer is cured. We must try to 
recognize, monitor and decrease the late effects of cancer therapy when possible and, if not 
possible, to understand the effects so that future treatment regimens can be designed with 
less risks of late effects. Remarkable improvement in cure rates has been achieved by persis-
tent stress on designing effective therapy. Only by continued, systematic follow-up of large 
cohorts of survivors will we know the full spectrum of damage caused by cytotoxic therapy 
and possible interventions that may mitigate the effects. Ongoing methods for educating both 
the patient and the primary caretakers must be devised. We must set up programs to evaluate 
the survivors to assess and care for chronic organ damage, providing the necessary support 
for the primary physician. As part of a collaborative effort, the primary care provider and the 
specialist must work toward the goal of best possible quality of life for the pediatric cancer 
survivor.
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